Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics.
We have characterized the interaction of the antitumor drug doxorubicin with model membranes of the anionic phospholipids dioleoylphosphatidic acid (DOPA), dioleoylphosphatidylserine (DOPS), cardiolipin and dioleoylphosphatidylglycerol (DOPG) as compared to the zwitterionic dioleoylphosphatidylcholine (DOPC) or dioleoylphosphatidylethanolamine (DOPE). The saturating binding levels were: 2.4 (DOPA), 1.3 (cardiolipin), 1.5 (DOPS, DOPG) and 0.02 (DOPC) doxorubicin per lipid phosphorus (mol/mol). The half-saturating free drug concentrations were comparable for DOPA, cardiolipin, DOPS and DOPG: 20, 16, 35 and 18 microM, respectively. Doxorubicin fluorescence revealed the simultaneous existence of at least two populations of bound drug in the various anionic phospholipids: (1) fluorescent molecules with chromophores that reside between the lipid molecules and (2) above 0.01-0.02 doxorubicin bound per lipid phosphorus: non-fluorescent drug-stacks that are closer to the aqueous phase than the fluorescent molecules. Small-angle X-ray scattering indicated that doxorubicin can reorganize anionic phospholipid dispersions into closely-packed multilamellar structures. Addition of the drug caused leakage of entrapped 6-carboxyfluorescein. Neither 2H-NMR on [2-2H]serine-labelled DOPS nor 31P-NMR revealed any significant effect of doxorubicin on headgroup conformation, but 2H-NMR on di[11,11-2H2]oleoyl-labelled phospholipids showed that the drug had a strong acyl chain-disordering effect on anionic phospholipids. 2H-NMR relaxation measurements indicated that the drug immobilized the headgroups and acyl chains of anionic phospholipids. The implications of these observations for the cellular activity of the drug are indicated.
de Wolf
F A
FA
Institute of Molecular Biology and Medical Biotechnology, University of Utrecht, The Netherlands.
Maliepaard
M
M
van Dorsten
F
F
Berghuis
I
I
Nicolay
K
K
de Kruijff
B
B
D000818:Animals; D002412:Cations / Q000378:metabolism; D002417:Cattle; D004317:Doxorubicin / Q000378:metabolism*; D005452:Fluoresceins; D005453:Fluorescence; D007700:Kinetics; D009682:Magnetic Resonance Spectroscopy; D008567:Membranes, Artificial; D010743:Phospholipids / Q000378:metabolism*; D010761:Phosphorus Radioisotopes; D014867:Water / Q000378:metabolism
D002412:Cations; D005452:Fluoresceins; D008567:Membranes, Artificial; D010743:Phospholipids; D010761:Phosphorus Radioisotopes; D014867:Water; C024098:6-carboxyfluorescein; D004317:Doxorubicin